Therapeutic plasma exchange in multiple sclerosis patients with an aggressive relapse: an observational analysis in a high-volume center

Therapeutic plasma exchange in multiple sclerosis patients with an aggressive relapse: an observational analysis in a high-volume center

An evidence-based treatment for a Multiple Sclerosis (MS) relapse is an intravenous administration of 3–5 g of Methylprednisolone. In case of insufficient effect or corticosteroids intolerance, the therapeutic plasma exchange (TPE) is indicated. To assess the clinical effect of TPE in treatment of r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2022-11, Vol.12 (1), p.18374-7, Article 18374
Hauptverfasser: Bunganic, R., Blahutova, S., Revendova, K., Zapletalova, O., Hradilek, P., Hrdlickova, R., Ganesh, A., Cermakova, Z., Bar, M., Volny, O.
Format: Artikel
Sprache:eng
Schlagworte:
631/378
692/308
692/617
Adolescent
Adrenal Cortex Hormones - therapeutic use
Adult
Age
Apheresis
Autoimmune diseases
Corticoids
Corticosteroids
Female
Females
Humanities and Social Sciences
Humans
Intolerance
Intravenous administration
Male
Methylprednisolone
Middle Aged
multidisciplinary
Multiple sclerosis
Multiple Sclerosis - drug therapy
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Patients
Plasma Exchange - methods
Recurrence
Retrospective Studies
Science
Science (multidisciplinary)
Sex differences
Steroid hormones
Steroids
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:An evidence-based treatment for a Multiple Sclerosis (MS) relapse is an intravenous administration of 3–5 g of Methylprednisolone. In case of insufficient effect or corticosteroids intolerance, the therapeutic plasma exchange (TPE) is indicated. To assess the clinical effect of TPE in treatment of relapse in patients with relapsing-remitting MS (RRMS), we enrolled 155 patients meeting the following criteria (study period: January 2011 to February 2021): (1) age > 18, (2) RRMS according to the McDonald´s 2017 criteria, (3) MS relapse and insufficient effect of corticosteroids/corticosteroids intolerance, (4) baseline EDSS 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-23356-w